durvalumab + S-1

Durvalumab + S-1 is a combination therapy consisting of two distinct agents used in oncology. Durvalumab is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that acts as an immune checkpoint inhibitor by blocking programmed cell death-ligand 1 (PD-L1). This blockade prevents PD-L1 from binding to its receptors, PD-1 and CD80, on T cells, thereby enhancing antitumor immune responses and promoting cytotoxic T cell activation against tumor cells[1][2][5][6]. Durvalumab is primarily indicated for the treatment of various cancers including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer, hepatocellular carcinoma, endometrial cancer, and urothelial carcinoma[2][3][4]. It was developed by AstraZeneca. S-1 is an oral fluoropyrimidine-based chemotherapy agent composed of tegafur (a prodrug of 5-fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase to increase 5-FU bioavailability), and oteracil potassium (to reduce gastrointestinal toxicity). It acts as a small molecule antimetabolite that inhibits DNA synthesis in rapidly dividing tumor cells. S-1 is widely used in Asia for gastric cancer and other solid tumors. The combination aims to leverage the immunomodulatory effects of durvalumab with the cytotoxic activity of S-1 for synergistic anticancer efficacy.

Other names

durvalumab + S-1